The Region IV RCE is the Southeastern Regional Center of Excellence in Emerging Infections and Biodefense or SERCEB. SERCEB has unified the major research institutions in Region IV, and has established collaborations with Oak Ridge National Laboratory in Oak Ridge, TN, the Centers for Disease Control and Prevention, Atlanta, GA, and the Vaccine Research Center at the NIH. The goals of SERCEB are to develop new vaccines, therapeutics, and diagnostics to better protect the nation against potential bioterrorist threats. This will be accomplished by interdisciplinary and collaborative research using cutting edge science. A major research focus is on novel vaccine development for orthopoxviruses, Bacillus anthracis and Yersinia pestis, with each program led by a team of internationally renowned investigators (Programs 1, 3, 4, and 5). Two immunology programs will interact synergistically with the vaccine programs: Program 6 will develop strategies to modulate innate immunity to enhance immune responses to select agents and vaccines, and Program 7 will develop strategies to enhance adaptive T and B immune responses to select agents and vaccines. New drug development will include rapid screening of existing compounds and development of entirety novel drugs against orthopoxviruses (Program 2), as well as therapeutics directed at innate immunity (Program 6), Anthrax (Program 5), and Yersinia pestis (Program 4). Multiple sophisticated cores will provide powerful assistance for development of vaccines, drugs, and diagnostics. SERCEB also will help to bring new investigators to the biodefense effort, through a combination of educational programs, support of innovative new projects, and synergistic interactions among some of the best investigators in relevant research in the nation.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-NBS-M (M2))
Program Officer
Hirschberg, Rona L
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Duke University
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Dethoff, Elizabeth A; Boerneke, Mark A; Gokhale, Nandan S et al. (2018) Pervasive tertiary structure in the dengue virus RNA genome. Proc Natl Acad Sci U S A 115:11513-11518
Graham, Rachel L; Deming, Damon J; Deming, Meagan E et al. (2018) Evaluation of a recombination-resistant coronavirus as a broadly applicable, rapidly implementable vaccine platform. Commun Biol 1:179
Qi, Xiaoxuan; Wang, Wenjian; Dong, Haohao et al. (2018) Expression and X-Ray Structural Determination of the Nucleoprotein of Lassa Fever Virus. Methods Mol Biol 1604:179-188
Kocher, Jacob F; Lindesmith, Lisa C; Debbink, Kari et al. (2018) Bat Caliciviruses and Human Noroviruses Are Antigenically Similar and Have Overlapping Histo-Blood Group Antigen Binding Profiles. MBio 9:
Dhanwani, Rekha; Huang, Qinfeng; Lan, Shuiyun et al. (2018) Establishment of Bisegmented and Trisegmented Reverse Genetics Systems to Generate Recombinant Pichindé Viruses. Methods Mol Biol 1604:247-253
Shao, Junjie; Liu, Xiaoying; Liang, Yuying et al. (2018) Assays to Assess Arenaviral Glycoprotein Function. Methods Mol Biol 1604:169-178
Huang, Qinfeng; Shao, Junjie; Liang, Yuying et al. (2018) Assays to Demonstrate the Roles of Arenaviral Nucleoproteins (NPs) in Viral RNA Synthesis and in Suppressing Type I Interferon. Methods Mol Biol 1604:189-200
Gunn, Bronwyn M; Jones, Jennifer E; Shabman, Reed S et al. (2018) Ross River virus envelope glycans contribute to disease through activation of the host complement system. Virology 515:250-260
Shao, Junjie; Liang, Yuying; Ly, Hinh (2018) Roles of Arenavirus Z Protein in Mediating Virion Budding, Viral Transcription-Inhibition and Interferon-Beta Suppression. Methods Mol Biol 1604:217-227
Wirawan, Melissa; Fibriansah, Guntur; Marzinek, Jan K et al. (2018) Mechanism of Enhanced Immature Dengue Virus Attachment to Endosomal Membrane Induced by prM Antibody. Structure :

Showing the most recent 10 out of 400 publications